The impact of 5-alpha reductase inhibitor vs. alpha-1 adrenergic receptor antagonists on course of prostate premalignant conditions

Adv Clin Exp Med. 2014 Jan-Feb;23(1):79-84. doi: 10.17219/acem/37025.

Abstract

Background: Prostate intraepithelial neoplasm and atypical small acinar proliferation are considered prostate premalignant conditions. Such a diagnosis impacts further follow-up significantly as early detection of prostate cancer is of utmost importance. alpha-1 adrenergic receptor antagonists (i.e. doxazosiunum) and inhibitors of 5-alpha reductase (Finasteride) showed some efficacy in prevention of prostate cancer development.

Objectives: To assess the impact of both above mentioned drugs on prostate premalignant conditions.

Material and methods: From January 2008 till September 2012, 213 patients with one of the above mentioned premalignant condition were retrospectively evaluated. after diagnosis they were assigned to group 1 (n-126)- treated with Finasteride or to group 2 (n-87)-treated with doxazosinum. every 6-7 months rebiopsies were conducted in each patient. Rate of remission and progression was assessed.

Results: In comparison between group 1 and 2 the rate of remission was 35.7% (n-45) vs. 18.4% (n-16) (p = 0.005). In terms of progression, the difference between 1st and 2nd group of patients was 7.1% (n-9) vs. 5.7% (n-5) (p = 0.68).

Conclusions: Remission of prostate premalignant condition is efficacious with Finasteride and not with doxazosinum. However, in terms of progression there were no differences among both drugs.

Publication types

  • Comparative Study

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use*
  • Adrenergic alpha-1 Receptor Antagonists / therapeutic use*
  • Aged
  • Finasteride / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Precancerous Conditions / drug therapy*
  • Prostatic Neoplasms / drug therapy*
  • Retrospective Studies

Substances

  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-1 Receptor Antagonists
  • Finasteride